Those Who Invested in Krystal Biotech (NASDAQ:KRYS) Five Years Ago Are up 329%
Those Who Invested in Krystal Biotech (NASDAQ:KRYS) Five Years Ago Are up 329%
Long term investing can be life changing when you buy and hold the truly great businesses. While the best companies are hard to find, but they can generate massive returns over long periods. Just think about the savvy investors who held Krystal Biotech, Inc. (NASDAQ:KRYS) shares for the last five years, while they gained 329%. And this is just one example of the epic gains achieved by some long term investors. In the last week shares have slid back 2.5%.
当你买入并持有真正优秀的业务时,长期投资可以改变人生。虽然最好的公司很难找到,但是在长期内它们可以带来巨大的回报。想一想那些持有Krystal Biotech, Inc.(NASDAQ:KRYS)股票五年的聪明投资者,他们赚了329%。这只是长期投资者实现的一次巨大收益的例子之一。在过去的一周里,股票已经下跌了2.5%。
Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns.
让我们长期看一下潜在的基本面,看看它们是否与股东回报一致。
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.
虽然市场是一个强大的定价机制,但股价反映了投资者情绪,不仅仅是基本业绩。一种有缺陷但合理的评估公司周围情绪如何变化的方法是将每股收益(EPS)与股价进行比较。
During the last half decade, Krystal Biotech became profitable. Sometimes, the start of profitability is a major inflection point that can signal fast earnings growth to come, which in turn justifies very strong share price gains.
在过去的五年中,Krystal Biotech实现了盈利。有时候,盈利的开始是一个重大的转折点,可以预示着未来快速的收益增长,这反过来又可以证明股价的大幅上涨是合理的。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
该公司的每股收益(随时间的推移)如下图所示(单击可查看确切数字)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240619/0-ff621402d6685ed1d716fe8077ab7caf-0-a51af65a166f4b3fb79e1a054ba34faa.png/big)
We know that Krystal Biotech has improved its bottom line lately, but is it going to grow revenue? This free report showing analyst revenue forecasts should help you figure out if the EPS growth can be sustained.
我们知道Krystal Biotech最近已经改善了其底线,但其营业收入是否会增长呢?这份提供分析师营业收入预测的免费报告应该可以帮助您确定EPS增长是否可持续。
A Different Perspective
不同的观点
It's good to see that Krystal Biotech has rewarded shareholders with a total shareholder return of 39% in the last twelve months. That gain is better than the annual TSR over five years, which is 34%. Therefore it seems like sentiment around the company has been positive lately. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Krystal Biotech has 2 warning signs (and 1 which is concerning) we think you should know about.
很高兴看到Krystal Biotech在过去12个月中为股东提供了39%的总股东回报。这个收益比5年期间的年度TSR(34%)要好。因此,目前公司周围的情绪似乎是积极的。在最好的情况下,这可能暗示着一些真正的业务动力,这意味着现在可能是深入研究其股票的好时机。尽管考虑市场条件可能对股价产生的不同影响是非常值得的,但有其他更重要的因素。拿风险来说,Krystal Biotech有2个警告信号(并且1个令人担忧),我们认为您应该知道。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.
如果您愿意查看另一家公司-具有潜在更优质财务状况的公司-则不要错过这个免费的公司列表,这些公司已经证明他们可以增长收益。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。